NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

That's an interesting point that you raise:

..... in the UK special program [is] the regimen in use the DCVax-L + Poly-ICLC?

As the special program relates solely to the DCVax-L component, surely it is up to the responsible clinician to decide whether or not the patient should be subjected to any additional treatment, be it poly-ICLC, pembrolizumab or both.